Impact of Inhibitor Development on the Cost Effectiveness of Prophylactic Treatment with Recombinant Factor VIII in Previously Untreated Patients with Severe Hemophilia A
{{output}}
Background/objectives: Inhibitor development against recombinant factor VIII (rFVIII) is a significant complication in the prophylactic treatment of severe hemophilia A. The economic impact of varying inhibitor risks among rFVIII... ...
